Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124251) titled 'Research on innovative intervention regimen and model for close contacts of drug sensitive tuberculosis patients' on May 9.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College

Condition: tuberculosis

Intervention: Preventive treatment trial protocol group:Isoniazid+Rifapentin (maximum dose 600 mg), twice a week for a total of 6 weeks Preventive treatment recommendation group:Isoniazid+Rifapentin (maximum dose 600 mg), twice a week for a total of 3 months Post exposure intervention group:Is...